Randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients, aged 11-45 years, with intermediate and poor-risk metastatic germ cell tumours. The aim of the trial is to compare the two treatment arms with respect to:
• Progression free survival (disease progression or death)
Globally 500 patients will be recruited, with approximately 170 patients being recruited from UK participating sites.